Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not-so-smiling Bob

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Postal Inspection and other federal agencies raided Berkeley Premium Nutraceuticals' Forest Park, Ohio headquarters March 16. The firm has an "unsatisfactory" record with the Cincinnati Better Business Bureau "due to a pattern of complaints concerning billing and refund issues," including more than 2,500 complaints processed in the last year. Berkeley says it is currently in discussions with FDA over product claims the agency believes violate the FD&C Act. The company markets the Enzyte "natural male enhancement" product in ads featuring the "Smiling Bob" character and has been cited by CBBB's NAD division for advertising claims (1"The Tan Sheet" Aug. 25, 2003, p. 16). Because the firm has implemented quality control systems and has seen a "dramatic decline" in consumer complaints, Berkeley "fails to understand the need" for the raid, CEO Steve Warshak said March 17...

You may also be interested in...



Enzyte Marketer Berkeley Settles Complaints For $2.5 Mil.

Berkeley Premium Nutraceuticals will pay $2.5 mil. in legal costs and restitution in accordance with a consent agreement, the firm announced March 1

Enzyte Male Enhancement Program Claims Overly Enhanced

Lifekey Healthcare should discontinue performance and efficacy claims for its Enzyte Male Enhancement Program, due in part to insufficient clinical evidence of the product's performance and efficacy, the National Advertising Division says

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel